Retension Pharmaceuticals CEO holds 402,577 shares
The preferred shares may convert into common stock and automatically convert immediately before the IPO closing without payment of consideration.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
3
Rhea-AI Filing Summary
Retension Pharmaceuticals, Inc. Chief Executive Officer Eric L. Keller reported direct ownership of 402,577 common shares on October 8, 2026. His reported holdings also include options for 80,516 shares at $1.43, expiring September 22, 2034, and options for 128,825 and 32,207 shares at $2.43, expiring October 30, 2035 and April 30, 2036, respectively. He also reported 9,662 Series A and 31,368 Series B preferred shares, each convertible into one common share.
Insider Trade Summary
6 transactions reported
Mixed
6 txns
Insider
Keller Eric L.
Role
Chief Executive Officer
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| holding | Stock Option (right to buy) F1 | -- | -- | -- |
| holding | Stock Option (right to buy) F2 | -- | -- | -- |
| holding | Stock Option (right to buy) F3 | -- | -- | -- |
| holding | Series A Convertible Preferred Stock F4 | -- | -- | -- |
| holding | Series B Convertible Preferred Stock F5 | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
Holdings After Transaction:
Stock Option (right to buy) — 241,548 contracts (Direct);
Series A Convertible Preferred Stock — 9,662 contracts (Direct);
Series B Convertible Preferred Stock — 31,368 contracts (Direct);
Common Stock — 402,577 shares (Direct)
Footnotes (5)
- F1. Granted to the Reporting Person on September 23, 2024. The stock options vest in 1/36 monthly increments, with the first vesting date on December 21, 2023, subject to the Reporting Person's continued service to the Issuer on each vesting date.
- F2. Granted to the Reporting Person on October 31, 2025. The stock options vest in 1/36 monthly increments, with the first vesting date on September 29, 2025, subject to the Reporting Person's continued service to the Issuer on each vesting date.
- F3. Granted to the Reporting Person on May 1, 2026. Twenty-five percent of the stock options vest on the first anniversary of the date of grant, with the remaining options vesting in equal quarterly installments thereafter, subject to the Reporting Person's continued service to the Issuer on each vesting date.
- F4. The Series A Convertible Preferred Stock (the "Series A Preferred Stock") is convertible into one share of Common Stock at any time at the option of the holder. The Series A Preferred Stock will automatically convert immediately prior to the closing of the Issuer's initial public offering into the number of shares shown in column 3 without payment of consideration. The Series A Preferred Stock has no expiration date.
- F5. The Series B Convertible Preferred Stock (the "Series B Preferred Stock") is convertible into one share of Common Stock at any time at the option of the holder. The Series B Preferred Stock will automatically convert immediately prior to the closing of the Issuer's initial public offering into the number of shares shown in column 3 without payment of consideration. The Series B Preferred Stock has no expiration date.
Key Figures
Direct common shares: 402,577 shares
Option underlying shares: 80,516 shares
Option exercise price: $1.43 per share
+5 more
8 metrics
Direct common shares
402,577 shares
Reported October 8, 2026
Option underlying shares
80,516 shares
$1.43 exercise price; expiration September 22, 2034
Option exercise price
$1.43 per share
Option covering 80,516 common shares
Option underlying shares
128,825 shares
$2.43 exercise price; expiration October 30, 2035
Option underlying shares
32,207 shares
$2.43 exercise price; expiration April 30, 2036
Option exercise price
$2.43 per share
Options covering 128,825 and 32,207 common shares
Series A Convertible Preferred Stock
9,662 shares
Each convertible into one common share
Series B Convertible Preferred Stock
31,368 shares
Each convertible into one common share
Key Terms
1/36 monthly increments, Series A Convertible Preferred Stock, Series B Convertible Preferred Stock, initial public offering
4 terms
1/36 monthly increments technical
"The stock options vest in 1/36 monthly increments"
Series A Convertible Preferred Stock financial
"convertible into one share of Common Stock"
Series A convertible preferred stock is a class of shares sold in an early funding round that gives investors a mix of protection and upside: it pays a priority claim over common shares if the company is sold or closes, but can be converted into ordinary shares to share in future growth. Think of it like a hybrid between a safer stake and a ticket to ownership; it matters to investors because it affects who controls the company, how future gains are split, and how much their investment is protected from downside.
Series B Convertible Preferred Stock financial
"automatically convert immediately prior to the closing"
Series B convertible preferred stock is a class of shares sold during a later-stage private financing that combines features of a loan and common stock: it usually pays priority dividends or has a priority claim if the company is sold, and it can be converted into common shares under predefined rules. Investors care because these shares affect ownership stakes and payout order—like having a reserved place in line and a ticket that can turn into regular ownership—so they influence potential returns and dilution for other shareholders.
initial public offering financial
"immediately prior to the closing of the Issuer's initial public offering"
An initial public offering (IPO) is when a private company first sells its shares to the public and becomes a stock-listed company. It matters because it allows the company to raise money from a wide range of investors, helping it grow, while giving early shareholders a way to sell some of their ownership.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What are the vesting terms for Eric L. Keller's RTSN stock options?
The options granted September 23, 2024 and October 31, 2025 vest in 1/36 monthly increments, with first vesting dates of December 21, 2023 and September 29, 2025, respectively. Options granted May 1, 2026 vest 25% on the first anniversary, then in equal quarterly installments; all vesting is subject to continued service.
AI-generated analysis. How Rhea-AI works. Not financial advice.
